Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project (IMPACT)

This study aims to screen tumor molecular profile for better selection of anticancer treatment, in particular, allocation to clinical trials if available.

Study Overview

• Status: Recruiting
• Conditions: Solid Tumor

Detailed Description

Molecular profiling will be performed on archival tumor tissue or freshly collected tumor tissue from re-biopsy. Blood, pleural fluid, FNA, and/or saliva may be collected to study the genetic makeup and also to compare the tumor molecular profile. Personalized therapy will be given based on molecular profile.

• Study Type: Observational
• Enrollment (Estimated): 5500

Contacts and Locations

• Study Contact: Name: Daniel SW Tan; Phone Number: +65 6436 8000; Email: daniel.tan.s.w@singhealth.com.sg

Study Locations

• Singapore
  • Singapore, Singapore
    • Recruiting
    • National Cancer Centre, Singapore

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Any advanced cancer patient who would benefit from molecular profiling and is a potential clinical trial candidate as identified by treating physician.

Description

Inclusion Criteria:

• Confirmed histological diagnosis of solid tumor
• Suitable for systematic treatment and clinical trials
• ECOG (Eastern cooperative oncology group) performance status < 2
• Able to provide tumor tissue for molecular profiling
• Able to understand and sign the informed consent form

Exclusion Criteria:

• None

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
tumor tissue for molecular profiling

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The molecular and clinical epidemiology for cancer patients being considered for novel therapeutics	5 years

Secondary Outcome Measures

Outcome Measure	Time Frame
The proportion of patients who have actionable alterations and enrol into clinical trials	5 years
The correlation of molecular profiles with clinical outcomes	5 years

Collaborators and Investigators

• Sponsor: National Cancer Centre, Singapore
• Investigators: Principal Investigator: Daniel SW Tan, National Cancer Centre, Singapore

Publications and helpful links

General Publications

• Chia S, Low JL, Zhang X, Kwang XL, Chong FT, Sharma A, Bertrand D, Toh SY, Leong HS, Thangavelu MT, Hwang JSG, Lim KH, Skanthakumar T, Tan HK, Su Y, Hui Choo S, Hentze H, Tan IBH, Lezhava A, Tan P, Tan DSW, Periyasamy G, Koh JLY, Gopalakrishna Iyer N, DasGupta R. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017 Sep 5;8(1):435. doi: 10.1038/s41467-017-00451-5.

Study record dates

Study Major Dates

• Study Start: October 1, 2011
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: June 16, 2016
• First Submitted That Met QC Criteria: June 17, 2016
• First Posted (Estimated): June 20, 2016

Study Record Updates

• Last Update Posted (Actual): May 13, 2026
• Last Update Submitted That Met QC Criteria: May 8, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: ECRU-IMPACT

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO